Performance of mergers and acquisitions in pharmaceutical industry: a comparative perspective

Mehmet Demirbag, Chang-Keong Ng, Ekrem Tatoglu

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    This study provides new evidence on the nature of value creation in M&A activity based on a sample of giant pharmaceutical M&As and independent non-M&A rival firms. Relying on multiple indicators of performance, their post-M&A performance was compared with their pre-M&A performance as well as with the performance of other major pharmaceutical firms that have not been involved in M&A activity. Based on three measures of operating M&A performance, it has been noted in general that no value creation was realized in the sample M&As in terms of research productivity, return on investment, and profit margin. The sample M&As had lower research productivity than that of both pre-M&A and independent non-M&A rival firms. In a similar vein, with regard to return on investment, M&As were not better than their pre-M&A firms, but performed relatively better than their non-M&A rivals. As far as the profit margin is concerned, the sample M&As, however, appeared to have better performance than pre-M&A firms and almost on par with the non-M&A rivals.
    Original languageEnglish
    Pages (from-to)41-61
    Number of pages21
    JournalMultinational Business Review
    Volume15
    Issue number2
    DOIs
    Publication statusPublished - 2007

    Fingerprint

    Pharmaceutical industry
    Mergers and acquisitions
    Value creation
    Research productivity
    Return on investment
    Pharmaceuticals
    Profit margin

    Keywords

    • acquisitions and mergers
    • pharmaceutical industry
    • performance evaluation

    Cite this

    Demirbag, Mehmet ; Ng, Chang-Keong ; Tatoglu, Ekrem. / Performance of mergers and acquisitions in pharmaceutical industry : a comparative perspective. In: Multinational Business Review. 2007 ; Vol. 15, No. 2. pp. 41-61.
    @article{264465dca2f44831942217b935df05d0,
    title = "Performance of mergers and acquisitions in pharmaceutical industry: a comparative perspective",
    abstract = "This study provides new evidence on the nature of value creation in M&A activity based on a sample of giant pharmaceutical M&As and independent non-M&A rival firms. Relying on multiple indicators of performance, their post-M&A performance was compared with their pre-M&A performance as well as with the performance of other major pharmaceutical firms that have not been involved in M&A activity. Based on three measures of operating M&A performance, it has been noted in general that no value creation was realized in the sample M&As in terms of research productivity, return on investment, and profit margin. The sample M&As had lower research productivity than that of both pre-M&A and independent non-M&A rival firms. In a similar vein, with regard to return on investment, M&As were not better than their pre-M&A firms, but performed relatively better than their non-M&A rivals. As far as the profit margin is concerned, the sample M&As, however, appeared to have better performance than pre-M&A firms and almost on par with the non-M&A rivals.",
    keywords = "acquisitions and mergers, pharmaceutical industry, performance evaluation",
    author = "Mehmet Demirbag and Chang-Keong Ng and Ekrem Tatoglu",
    year = "2007",
    doi = "10.1108/1525383X200700007",
    language = "English",
    volume = "15",
    pages = "41--61",
    journal = "Multinational Business Review",
    issn = "1525-383X",
    publisher = "Emerald Publishing Limited",
    number = "2",

    }

    Performance of mergers and acquisitions in pharmaceutical industry : a comparative perspective. / Demirbag, Mehmet; Ng, Chang-Keong; Tatoglu, Ekrem.

    In: Multinational Business Review, Vol. 15, No. 2, 2007, p. 41-61.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Performance of mergers and acquisitions in pharmaceutical industry

    T2 - a comparative perspective

    AU - Demirbag, Mehmet

    AU - Ng, Chang-Keong

    AU - Tatoglu, Ekrem

    PY - 2007

    Y1 - 2007

    N2 - This study provides new evidence on the nature of value creation in M&A activity based on a sample of giant pharmaceutical M&As and independent non-M&A rival firms. Relying on multiple indicators of performance, their post-M&A performance was compared with their pre-M&A performance as well as with the performance of other major pharmaceutical firms that have not been involved in M&A activity. Based on three measures of operating M&A performance, it has been noted in general that no value creation was realized in the sample M&As in terms of research productivity, return on investment, and profit margin. The sample M&As had lower research productivity than that of both pre-M&A and independent non-M&A rival firms. In a similar vein, with regard to return on investment, M&As were not better than their pre-M&A firms, but performed relatively better than their non-M&A rivals. As far as the profit margin is concerned, the sample M&As, however, appeared to have better performance than pre-M&A firms and almost on par with the non-M&A rivals.

    AB - This study provides new evidence on the nature of value creation in M&A activity based on a sample of giant pharmaceutical M&As and independent non-M&A rival firms. Relying on multiple indicators of performance, their post-M&A performance was compared with their pre-M&A performance as well as with the performance of other major pharmaceutical firms that have not been involved in M&A activity. Based on three measures of operating M&A performance, it has been noted in general that no value creation was realized in the sample M&As in terms of research productivity, return on investment, and profit margin. The sample M&As had lower research productivity than that of both pre-M&A and independent non-M&A rival firms. In a similar vein, with regard to return on investment, M&As were not better than their pre-M&A firms, but performed relatively better than their non-M&A rivals. As far as the profit margin is concerned, the sample M&As, however, appeared to have better performance than pre-M&A firms and almost on par with the non-M&A rivals.

    KW - acquisitions and mergers

    KW - pharmaceutical industry

    KW - performance evaluation

    U2 - 10.1108/1525383X200700007

    DO - 10.1108/1525383X200700007

    M3 - Article

    VL - 15

    SP - 41

    EP - 61

    JO - Multinational Business Review

    JF - Multinational Business Review

    SN - 1525-383X

    IS - 2

    ER -